

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Steven Gourlay
Date of last notice	26 March 2026

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	2. SG Gourlay Nominees Pty Ltd <SG Gourlay Family A/C> - Director of trustee and beneficiary of trust
Date of change	13 May 2026
No. of securities held prior to change	1. 89,362,300 fully paid ordinary shares issued pursuant to Employee Share Plan. 52,908,703 fully paid ordinary shares. 702,864 unlisted options ex @ \$0.0375 exp 11/9/2026 1,757,440 listed options ex @ \$0.05 exp 31/5/2027 25,000,000 listed options ex \$0.05 exp 30/9/2027 2. 20,561,907 fully paid ordinary shares. 1,739,783 unlisted options ex @ \$0.0375 exp 11/9/2026 642,560 listed options ex @ \$0.05 exp 31/5/2027
Class	Fully paid ordinary shares Unlisted options ex @\$0.0375 exp 11/9/2026
Number acquired	1. 702,864 fully paid ordinary shares 2. 1,739,783 fully paid ordinary shares
Number disposed	1. 702,864 unlisted options ex @\$0.0375 exp 11/9/2026 2. 1,739,783 unlisted options ex @\$0.0375 exp 11/9/2026

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation	\$91,599.26
No. of securities held after change	89,362,300 fully paid ordinary shares issued pursuant to Employee Share Plan. 53,611,567 fully paid ordinary shares. 1,757,440 listed options ex @ \$0.05 exp 31/5/2027 25,000,000 listed options ex \$0.05 exp 30/9/2027 22,301,690 fully paid ordinary shares. 642,560 listed options ex @ \$0.05 exp 31/5/2027
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of unlisted options ex @\$0.0375 exp 11/9/2026

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.